AU Patent

AU2008202652B2 — Enteric solid oral dosage form of bisphosphonate containing a chelating agent

Assigned to Theramex HQ UK Ltd · Expires 2010-02-11 · 16y expired

What this patent protects

Patent listed against risedronate-sodium.

Drugs covered by this patent

risedronate-sodium (RISEDRONATE SODIUM)

Patent Metadata

Patent number: AU2008202652B2
Jurisdiction: AU
Classification: —
Expires: 2010-02-11
Drug substance claim: No
Drug product claim: No
Assignee: Theramex HQ UK Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.